Table 1.
Cases characteristics of SSIBs associated with GLP-1RA in the FAERS database
| Categories | Semaglutide N (%) | Liraglutide N (%) | Dulaglutide N (%) | Exenatide N (%) | Albiglutide N (%) | Total N (%) |
|---|---|---|---|---|---|---|
| Reports of SSIBs | 57 | 74 | 51 | 20 | 2 | 204 |
| Report year | ||||||
| 2018 | 2 (3.51) | 16 (21.62) | 12 (23.53) | 4 (20.00) | 1 (50.00) | 35 (17.16) |
| 2019 | 4 (7.02) | 11 (14.86) | 7 (13.73) | 7 (35.00) | 0 | 29 (14.22) |
| 2020 | 8 (14.04) | 19 (25.68) | 10 (19.61) | 4 (20.00) | 1 (50.00) | 42 (20.59) |
| 2021 | 16 (28.07) | 12 (16.22) | 8 (15.69) | 2 (10.00) | 0 | 38 (18.63) |
| 2022 | 27 (47.37) | 16 (21.62) | 14 (27.45) | 3 (15.00) | 0 | 60 (29.41) |
| Reporter a | ||||||
| Healthcare professional | 30 (52.63) | 53 (71.62) | 19 (37.25) | 9 (45.00) | 1 (50.00) | 112 (54.90) |
| Nonhealthcare professional | 26 (45.61) | 21 (28.38) | 31 (60.78) | 6 (30.00) | 1 (50.00) | 85 (41.67) |
| Unknown or missing | 1 (1.75) | 0 | 1 (1.96) | 5 (25.00) | 0 | 7 (3.43) |
| Sex | ||||||
| Male | 18 (31.58) | 20 (27.03) | 19 (37.25) | 9 (45.00) | 1 (50.00) | 67 (32.84) |
| Female | 38 (66.67) | 52 (70.27) | 29 (56.86) | 11 (55.00) | 1 (50.00) | 131 (64.22) |
| Unknown or missing | 1 (1.75) | 2 (2.70) | 3 (5.88) | 0 | 0 | 6 (2.94) |
| Age category, years | ||||||
| Juvenile (< 18) | 0 | 0 | 0 | 3 (15.00) | 0 | 3 (1.47) |
| Adult (18–65) | 28 (49.12) | 43 (58.11) | 24 (47.06) | 7 (35.00) | 0 | 102 (50.00) |
| Seniors (> 65) | 1 (1.75) | 7 (9.46) | 10 (19.61) | 2 (10.00) | 0 | 20 (9.80) |
| Unknown or missing | 28 (49.12) | 24 (32.43) | 17 (33.33) | 8 (40.00) | 2 (100.00) | 79 (38.73) |
| Median (IQR) | 43 (35–52) | 47 (36–57) | 55 (46–67) | 40 (25–54) | / | / |
| Indication | ||||||
| Type 2 diabetes mellitus | 13 (22.81) | 14 (18.92) | 30 (58.82) | 13 (65.00) | 1 (50.00) | 71 (34.80) |
| Weight loss | 15 (26.32) | 15 (20.27) | 0 | 0 | 0 | 30 (14.71) |
| Others | 1 (1.75) | 4 (5.41) | 0 | 3 (15.00) | 0 | 8 (3.92) |
| Unknown or missing | 28 (49.12) | 41 (55.41) | 21 (41.18) | 4 (20.00) | 1 (50.00) | 95 (46.57) |
| Outcomesb | ||||||
| Death | 1 (1.75) | 17 (22.97) | 3 (5.88) | 1 (5.00) | 0 | 22 (10.78) |
| Life-threatening | 6 (10.53) | 6 (8.11) | 3 (5.88) | 5 (25.00) | 0 | 20 (9.80) |
| Hospitalization | 8 (14.04) | 20 (27.03) | 19 (37.25) | 7 (35.00) | 0 | 54 (26.47) |
| Disability | 2 (3.51) | 1 (1.35) | 2 (3.92) | 1 (5.00) | 0 | 6 (2.94) |
| Other serious illness | 52 (91.23) | 55 (74.32) | 37 (72.55) | 12 (60.00) | 2 (100) | 158 (77.45) |
IQR interquartile range, SSIBs Suicidal and Self-Injurious Behaviors, GLP-1RAs GLP-1 receptor agonists
aHealthcare professionals including reporters such as physicians and pharmacists; nonhealthcare professionals including reporters such as consumer and lawyer
bSince a case may experience different clinical outcomes during drug therapy, it is reasonable that the sum percentage of the outcome under this item may exceed 100%